JMP Securities analyst Silvan Tuerkcan initiated coverage of Acrivon Therapeutics with an Outperform rating and $14 price target. Acrivon is a clinical-stage biotechnology company focused on developing precision therapeutics using its unique phosphoproteomics-based AP3 technology, the analyst tells investors in a research note. Currently trading below cash, the company is an “interesting, overlooked opportunity” applying a next-generation biomarker strategy to a de+risked and safe asset, originally developed by Array BioPharma, says the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACRV:
- Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
- Acrivon Therapeutics Welcomes New Board Member Dr. Magovcevic-Liebisch
- Acrivon Therapeutics appoints Magovcevic to board of directors
- Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
